UK-414,495
Prijeđi na navigaciju
Prijeđi na pretragu
![]() | |||
(IUPAC) ime | |||
---|---|---|---|
(R)-2-({1-[(5-etil-1,3,4-tiadiazol-2-il)karbamoil]ciklopentil}metil)valerinska kiselina | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 337962-93-3 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 9949799 | ||
Hemijski podaci | |||
Formula | C16H25N3O3S | ||
Mol. masa | 339,452 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
UK-414,495 je lek koji je razvila kompanija Pfizer za tretman poremećaja ženskog seksualnog nadražaja.[3] UK-414,495 deluje kao potentan i selektivan inhibitor enzima neutralna endopeptidaza, čija normalna funkcija je razlaganje neuropeptida VIP. Konsekventno povećanje VIP aktivnosti menja protok krvi u genitalnom regionu, što dovodi do povećanja lubrikacije i mišične relaksacije.[4][5][6]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ 'Female Viagra' will help women increase their sexual arousal. Daily Mail Online 14th April 2010
- ↑ Armer R, Warne P, Witherington J (2006). „Recent disclosures of clinical drug candidates”. Drug News & Perspectives 19 (1): 65–72. PMID 16550257. ISSN 0214-0934
- ↑ Angulo J. (2010). „Neutral endopeptidase inhibition: could it have a role in the treatment of female sexual arousal disorder?”. British Journal of Pharmacology 160: 48. DOI:10.1111/j.1476-5381.2010.00693.x.
- ↑ Wayman C., Baxter D., Turner L., Van Der Graaf P., Naylor A. (2010). „UK-414,495, a selective inhibitor of neutral endopeptidase, potentiates pelvic nerve-stimulated increases in female genital blood flow in the anaesthetized rabbit”. British Journal of Pharmacology 160 (1): 51–59. DOI:10.1111/j.1476-5381.2010.00691.x. PMC 2860206. PMID 20412068.